RNAEDIT SIGNED
RNA EDITING IN HEALTH AND DISEASE
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RNAEDIT project word cloud
Explore the words cloud of the RNAEDIT project. It provides you a very rough idea of what is the project "RNAEDIT" about.
Project "RNAEDIT" data sheet
The following table provides information about the project.
| Coordinator |
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 2˙270˙000 € |
| EC max contribution | 2˙270˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2014-CoG |
| Funding Scheme | ERC-COG |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG | DE (HEIDELBERG) | coordinator | 1˙839˙172.00 |
| 2 | KAROLINSKA INSTITUTET | SE (STOCKHOLM) | participant | 430˙827.00 |
| 3 | THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE | UK (CAMBRIDGE) | participant | 0.00 |
Map
Project objective
'RNA editing is a type of programmed RNA sequence alteration that can result in a range of proteomic changes, from subtle fluctuations in output, to specific alterations in protein content. Editing is catalyzed by two classes of deaminases: those which convert adenosine to inosine (ADARs) and those which convert cytosine to uracil (APOBEC1). We have previously shown that APOBEC1-catalyzed editing in the transcriptome of macrophages leads to the generation of populations that are heterogeneous, and functionally diverse, enabling rapid population adaptation to different environmental settings.
Our first aim for this proposal is to extend our studies to additional immune cell subsets, focusing on cells that are recently recognized as 'plastic' to define the contribution of editing to this plasticity of fate and function.
RNA editing of the type we study has also been demonstrated to be crucial for cancer progression. For instance, APOBEC1-deficiency significantly reduces tumour burden on cells of the intestine and colon that are prone to adenocarcinomas in the context of the APC-min mutation. This is also the case for testicular carcinomas in mouse models of such tumours. Thus, there is genetic evidence for a requirement for APOBEC1 and RNA editing to drive tumour progression, in two tumour contexts. Based on these data and on our recently deciphered role for APOBEC1 as a 'stealthy' diversifier of cellular transcriptomes (and proteomic outcomes), we hypothesize that APOBEC1 drives tumour progression by editing select transcripts in tumour cells (or tumour stem cells), thus enabling the rapid adaptation of the tumour to the onslaught of the immune response.
Our second aim is to characterize the subset of edited transcripts in these model tumours (either at the population or at the single cell level) and understand their role to tumour survival and progression, both in mouse models of disease, and in human tumour samples (in collaboration with QP Hammarstrom, KI).'
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Violeta Rayon-Estrada, Dewi Harjanto, Claire E. Hamilton, Yamina A. Berchiche, Emily Conn Gantman, Thomas P. Sakmar, Karen Bulloch, Khatuna Gagnidze, Sheila Harroch, Bruce S. McEwen, F. Nina Papavasiliou Epitranscriptomic profiling across cell types reveals associations between APOBEC1-mediated RNA editing, gene expression outcomes, and cellular function published pages: 13296-13301, ISSN: 0027-8424, DOI: 10.1073/pnas.1714227114 |
Proceedings of the National Academy of Sciences 114/50 | 2019-06-07 |
| 2017 |
Daniel C. Cole, Youngcheul Chung, Khatuna Gagnidze, Kaitlyn H. Hajdarovic, Violeta Rayon-Estrada, Dewi Harjanto, Benedetta Bigio, Judit Gal-Toth, Teresa A. Milner, Bruce S. McEwen, F. Nina Papavasiliou, Karen Bulloch Loss of APOBEC1 RNA-editing function in microglia exacerbates age-related CNS pathophysiology published pages: 13272-13277, ISSN: 0027-8424, DOI: 10.1073/pnas.1710493114 |
Proceedings of the National Academy of Sciences 114/50 | 2019-06-07 |
| 2018 |
Khatuna Gagnidze, Violeta Rayon-Estrada, Sheila Harroch, Karen Bulloch, F. Nina Papavasiliou A New Chapter in Genetic Medicine: RNA Editing and its Role in Disease Pathogenesis published pages: 294-303, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2018.01.002 |
Trends in Molecular Medicine 24/3 | 2019-06-07 |
| 2019 |
Taga Lerner, F. Papavasiliou, Riccardo Pecori RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease published pages: 13, ISSN: 2073-4425, DOI: 10.3390/genes10010013 |
Genes 10/1 | 2019-08-30 |
| 2019 |
Mitchell Kluesner, Annette Arnold, Taga Lerner, Rafail Nikolaos Tasakis, Sandra Wüst, Marco Binder, Branden S. Moriarity, Riccardo Pecori MultiEditR: An easy validation method for detecting and quantifying RNA editing from Sanger sequencing published pages: , ISSN: , DOI: 10.1101/633685 |
BioarXiv | 2019-08-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RNAEDIT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RNAEDIT" are provided by the European Opendata Portal: CORDIS opendata.